Moderna, Inc. $MRNA Shares Sold by Groupe la Francaise

Key Points

• Groupe la Francaise has significantly reduced its stake in Moderna, Inc. by 63.1%, now holding 10,005 shares worth approximately $284,000 after selling 17,105 shares in the first quarter.
• Moderna's quarterly earnings report showed a loss of $2.13 per share, but exceeded analysts' expectations with revenue of $142 million compared to estimates of $116.26 million.
• Analysts have recently adjusted price targets on Moderna, with UBS lowering their target from $78 to $70 and Barclays cutting theirs from $40 to $31, indicating a more cautious outlook for the stock.

Groupe la Francaise reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 63.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,005 shares of the company's stock after selling 17,105 shares during the period. Groupe la Francaise's holdings in Moderna were worth $284,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. AlphaQuest LLC raised its position in shares of Moderna by 127.8% during the 1st quarter. AlphaQuest LLC now owns 4,585 shares of the company's stock valued at $130,000 after acquiring an additional 2,572 shares in the last quarter. Allstate Corp raised its position in shares of Moderna by 51.9% during the 1st quarter. Allstate Corp now owns 14,448 shares of the company's stock valued at $410,000 after acquiring an additional 4,934 shares in the last quarter. Norinchukin Bank The raised its position in shares of Moderna by 14.4% during the 1st quarter. Norinchukin Bank The now owns 16,665 shares of the company's stock valued at $472,000 after acquiring an additional 2,103 shares in the last quarter. Aufman Associates Inc raised its position in shares of Moderna by 34.4% during the 1st quarter. Aufman Associates Inc now owns 14,874 shares of the company's stock valued at $463,000 after acquiring an additional 3,808 shares in the last quarter. Finally, Humankind Investments LLC raised its position in shares of Moderna by 8.2% during the 1st quarter. Humankind Investments LLC now owns 15,606 shares of the company's stock valued at $442,000 after acquiring an additional 1,179 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on MRNA shares. William Blair reissued a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a research note on Sunday, July 13th. UBS Group lowered their price objective on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Barclays lowered their price objective on Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a research note on Monday, August 4th. Finally, Leerink Partners lowered their price objective on Moderna from $18.00 to $15.00 and set an "underperform" rating for the company in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have given a Hold rating and four have assigned a Sell rating to the company's stock. According to MarketBeat, Moderna currently has an average rating of "Hold" and an average target price of $42.88.

Moderna Stock Performance

NASDAQ:MRNA opened at $27.12 on Monday. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $84.28. The stock has a market cap of $10.55 billion, a price-to-earnings ratio of -3.60 and a beta of 1.83. The business has a fifty day moving average of $29.18 and a 200-day moving average of $29.05.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. During the same quarter in the prior year, the business posted ($3.33) earnings per share. The company's revenue for the quarter was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.